血克劳丁-5与年龄和阿尔茨海默病的关联
Keisuke Tachibana1, Ryuichi Hirayama2, Naoyuki Sato2,3
1Graduate School of Pharmaceutical Sciences, Osaka University, Suita 565-0871, Osaka, Japan.
International journal of molecular sciences
|February 10, 2024
概括
研究人员开发了克劳丁-5 (CLDN-5) 的血液测试,在阿尔茨海默病 (AD) 患者中发现了高水平. 这种基于血液的CLDN-5测定显示了作为AD和相关认知障碍的诊断标记物的潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 血脑屏障 (BBB) 对大脑功能至关重要,维护内皮细胞的完整性.
- BBB功能障碍与轻度认知障碍 (MCI) 和阿尔茨海默病 (AD) 有关.
- 克劳丁-5 (CLDN-5) 是一个关键蛋白质,负责密封BBB.
研究的目的:
- 开发一种基于血液的克劳丁-5 (CLDN-5) 检测试剂.
- 评估血CLDN-5在区分AD和MCI与对照中的诊断实用性.
- 探索CLDN-5酸化 (pTau181) 与认知衰退中的年龄之间的关系.
主要方法:
- 开发了一种血试验来测量克劳丁-5 (CLDN-5) 水平.
- 在100名对照组,100名MCI和100名AD患者中分析了CLDN-5和酸化 (pTau181).
- 与年龄和认知状态相关的生物标志物水平.
主要成果:
- 与对照组相比,AD患者的血CLDN-5水平 (3.08 ng/mL) 与对照组 (2.77 ng/mL) 相比显著更高.
- 与对照组 (1.81 pg/mL) 相比,MCI (2.86 pg/mL) 和AD (4.20 pg/mL) 患者的酸化 (pTau181) 水平都增加了.
- 血CLDN-5,但不是pTau181,在MCI和AD患者中随着年龄的增长而下降,表明与年龄相关的BBB变化.
结论:
- 血CLDN-5显示出作为诊断阿尔茨海默病的生物化学标记物的潜力.
- 在BBB完整性的年龄相关变化可能与MCI和AD的认知衰退有关.
- 该CLDN-5试验为非侵入性AD诊断提供了一个有希望的途径.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113


